Gufic Biosciences Limited has informed the Exchange about Acquisition

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

GUFICBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.1%Reaction day

₹389.05

prior close

₹360.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-6.2% vs market

Pharmaceuticals peers, median of 147sector-0.1%-6.1% vs sector

On the reaction day the stock moved 6.2 pts less than Nifty Microcap 250 and 6.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+1.6

15m

+2.1

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.1+0.1-6.2-0.1-6.1

Next day

-6.3-0.2-6.1-0.2-6.2

-4.6+0.3-4.9-0.2-4.3

-5.1+0.9-5.9+0.0-5.1

-5.2+0.8-5.9+0.0-5.2

-4.7+2.2-6.8+0.6-5.3

-4.4+3.4-7.7+1.4-5.8

15d

-11.3-0.8-10.5-2.9-8.4

-10.0+2.9-13.0+0.3-10.3

-2.3+0.8-3.2-0.4-2.0

-5.4+0.0-5.4-3.2-2.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gufic Biosciences Limited has informed the stock exchange about an acquisition. The company has not disclosed further details such as the name of the target entity, deal value, consideration type, or completion timeline in this filing. Investors would need to refer to the company's detailed disclosure or subsequent filings for specifics on what is being acquired and the financial impact.

Likely market impact

Acquisitions can be value-accretive or dilutive depending on the target and price paid; without further details on deal size, target, and funding source, shareholders should wait for more clarity before drawing conclusions on potential stock price impact.